Press release
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapy LONDON and NEW
About this update from Meiragtx Holdings Plc
[{"type":"text","content":"RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapy\nLONDON and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced a poster presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-oncology, which is being held from August 1-2, 2023, in Seattle, WA. “We are pleased to share data at this year's ASGCT Spotlight on Immuno-oncology on our RiboCAR technology, a synthetic riboswitch-based gene regulation system with the potential to transform CAR-T cell therapy,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “This innovative approach allows us to precisely and reversibly control the expression of CAR in a dose response to novel small molecule inducers, from undetectable at baseline to at least as high as levels of consitutively expressed CAR driven by the small molecule dose. This degree of control of timing and level of CAR expression is unprecedented.” Dr. Forbes continued, “The impact of precise CAR control appears to be profound. We have demonstrated impressive improvement in CAR-T activity, cell differentiation state and durability in response to regulated RiboCAR expression as well as providing a much needed safety switch. We believe this is a game changing technology with the potential to have meaningful impact on outcomes for patients treated with CAR-T therapy.” The poster will be available on the Posters and Publications page of the Company’s website on August 1, 2023. The details of the poster presentation are as follows: Poster Number: 21 Abstract Title: Riboswitch-regulated Chimeric Antigen Receptor (RiboCAR) Enhances CAR-T cell Anti-cancer EfficacyDate: August 1-2, 2023Time: 7:00am - 10:00amRoom: Emerald Ballroom Chimeric antigen receptor (CAR)-T cell therapy is a promising treatment for certain cancers. However, it is increasingly evident that the level and timing of CAR molecule expression is important for CAR-T cell activation, durability and anti-cancer activities. Here, we present the development of RiboCAR, a system for precise control of CAR expression via orally available small molecule inducers. Unlike previously reported regulatable CAR platfo...